Emerging evidence shows that suboptimal glycaemic control is associated with increased morbidity and length of stay in hospital. Various guidelines for safe and effective inpatient glycaemic control in the non-critical care setting have been published. In spite of this, implementation in practice remains limited because of the increasing number of people with diabetes admitted to hospital and staff work burden. The use of technology in the outpatient setting has led to improved glycaemic outcomes and quality of life for people with diabetes. There remains an unmet need for technology utilisation in inpatient hyperglycaemia management in the non-critical care setting. Novel technologies have the potential to provide benefits in diabetes care in hospital by improving efficacy, safety and efficiency. Rapid analysis of glucose measurements by point-of-care devices help facilitate clinical decision-making and therapy adjustment in the hospital setting. Glucose treatment data integration with computerized glucose management systems underpins the effective use of decision support systems and may streamline clinical staff workflow. Continuous glucose monitoring and automation of insulin delivery through closed-loop systems may provide a safe and efficacious tool for hospital staff to manage inpatient hyperglycaemia whilst reducing staff workload. This review summarizes the evidence with regard to technological methods to manage inpatient glycaemic control, their limitations and the future outlook, as well as potential strategies by healthcare organizations such as the National Health Service to mediate the adoption, procurement and use of diabetes technologies in the hospital setting.
Introduction
The growing prevalence of diabetes and increased longevity have escalated the burden of inpatient dysglycaemia, affecting nearly all areas of hospital care [1, 2] . Suboptimal glycaemic control in hospital is associated with adverse clinical outcomes and prolonged length of stay [3, 4] . Inpatient hyperglycaemia represents a considerable portion of national and international healthcare expenditure related to diabetes [5] . There are growing concerns about the safety and quality of inpatient hyperglycaemia management as staffing levels are being stretched, whilst the prevalence and complexity of cases increase.
Diabetes technology has progressed greatly over the past decade [6] . Advances in glucose monitoring and insulin delivery systems have improved clinical outcomes and quality of life for people with Type 1 diabetes in the outpatient setting. The use of factory-calibrated subcutaneous glucose monitoring, licensed for non-adjuvant insulin dosing, has been shown to attenuate hypoglycaemic risk, whilst reducing the burden of capillary blood glucose testing [7, 8] . Automated insulin delivery systems, known as the artificial pancreas or closed-loop system, have been shown in free-living unsupervised home studies to improve glycaemic control and to reduce the burden of hypoglycaemia in people with Type 1 diabetes [9, 10] , and emerging data suggest that automated insulin delivery technology may also benefit the inpatient hyperglycaemia management of people with Type 2 diabetes [11, 12] .
The aim of the present review is to provide an overview of the current status and future outlook of diabetes technology in the non-critical care setting. In-depth reviews of guidelines and evidence with regard to inpatient hyperglycaemia, and pharmacological and educational approaches to support Correspondence to: Hood Thabit. E-mail: hood.thabit@mft.nhs.uk inpatient diabetes management have been published elsewhere [13, 14] . An electronic search of Medline (via Pubmed) and the public register of clinical trials (www.clinicaltrials. org) was conducted. Keywords (inpatient hyperglycaemia, non-critical care, general wards, insulin therapy, glucose monitoring, computerized ordering, technology, closed-loop system) combined with relevant Medical Subject Headings (MeSH) terms were used. A secondary search strategy was conducted using these keywords and terms in the abstract databases from the American Diabetes Association (ADA) scientific sessions, and the bibliographies of retrieved papers were searched. Additional papers known to the authors were also used.
Inpatient hyperglycaemia management in non-critical care

Current status
Observational studies and audits from several countries have highlighted the shortcomings of current inpatient diabetes management. Approximately one-third of non-critical care inpatients in 575 US hospitals were reported to have hyperglycaemia, based on point-of-care glucose monitoring (POC-GM) measurements of >10 mmol/l [15] . This included people with known diabetes, as well as those newly diagnosed or with stress hyperglycaemia (defined by the ADA as any blood glucose concentration in hospital >7.8 mmol/l). Approximately 60% of those with stress hyperglycaemia are known to develop diabetes after 1 year [16] . Approximately 6% of non-critical care patient-days were reported to be in the hypoglycaemic range (<3.9 mmol/l).
In the UK, the National Diabetes Inpatient Audit included reports on the provision and management of inpatient glucose control [2] . The audit showed that current inpatient hyperglycaemia management in the UK remains suboptimal, as inpatients spent approximately half of their time in hospital with poorly controlled blood glucose levels. Insulin management errors were also highlighted, raising safety concerns. Almost half of insulin-treated patients had a medication error related to their insulin therapy, such as incorrect or unclear prescription, and administration of insulin at the wrong time. Other findings related to suboptimal inpatient glucose control included not increasing insulin dosage when blood glucose levels were persistently >11 mmol/l, or not reducing insulin dosage after unexplained glucose levels <4 mmol/l.
Evidence and guidelines
Improving glucose control in certain cohorts in the noncritical care setting has been shown to be associated with improved clinical outcomes [17] ; however, current evidence remains controversial and at times somewhat contradictory [18] . Most of the data were collected during observational and retrospective studies, which may be affected by bias and confounders. In contrast to critical care settings [19, 20] , few prospective randomized controlled trials evaluating tighter glycaemic control in non-critical care settings have been published [21] , and those studies were performed mostly in large academic and tertiary hospitals, where findings and practice may not be generalizable to other hospitals. A metaanalysis of 19 studies (nine randomized controlled studies, 10 observational studies) reported that intensive glycaemic control in the general ward was associated with a 59% reduction in the risk of infections [17] . The benefit of tighter glycaemic control was observed mostly in post-cardiac and general surgery inpatients. Additionally, in those groups where the pre-selected glycaemic goal was achieved, the relative risk of hypoglycaemia was increased by 58%, although the absolute risks in the intervention and control groups were low, The increased risk of hypoglycaemia highlights the need for closer inpatient glucose monitoring and for review of anti-hyperglycaemic therapies in hospitalized patients. These have led professional organizations to develop clinical guidelines for inpatient hyperglycaemia management in the non-critical care settings. Based on the available evidence and consensus, the ADA recently recommended that insulin therapy be initiated if there is persistent hyperglycaemia ≥10.0 mmol/l, and that the majority of non-critically ill patients should have a target glucose range of 7.8-10.0 mmol/l [22] . The avoidance of hypoglycaemia was emphasized, and elevated target glucose levels suggested according to clinical status and risk of hypoglycaemia, such as during palliative care and in elderly patients. The guideline recommends discontinuation of oral hypoglycaemic agents because of potential contraindication during inpatient stay, such as renal failure, and suggests the use of basal-bolus subcutaneous insulin therapy in combination with corrective insulindosing scales. It also recommends that timing of glucose measurements should match individual nutritional intake and for those who are fasting, who are unable to have any oral intake or who are on enteral feeding, blood glucose should be measured every 4-6 h.
Recommendations in the UK differ from those in the USA [23] . In the UK, recent national audit data show that it is standard practice to continue usual diabetes medications in hospital, which include oral hypoglycaemic agents, unless there are contraindications [24] . Those with normal What's new?
• There remains an unmet need for methods to reduce the burden of inpatient hyperglycaemia management in non-critical care settings.
• Innovative approaches, such as computerized decision support and automated insulin delivery systems, may reduce the risk of errors and improve glucose control in hospital.
ª 2017 Diabetes UK nutritional intake are usually allowed to continue their own established insulin therapy, with input on insulin dose titration from the clinical team. National audit data reporting on adherence to the ADA recommendations [22] have yet to be published. The Joint British Diabetes Societies for Inpatient Care have produced several healthcare professional guidelines related to hospital management of hyper-and hypoglycaemia, and glucose control management of inpatients receiving steroids, enteral feeding or undergoing surgery [14] . These guidelines generally recommend inpatient blood glucose levels <10.0 mmol/l in most cases, and taking pre-emptive measures to avoid hypoglycaemia.
Implementation challenges
In spite of the above recommendations, glucose control in the non-critical care setting remains suboptimal, with 20% of inpatients still experiencing hypoglycaemia in hospital [2, 25] . Several key areas for improvement have been outlined by National Diabetes Inpatient Audit, such as educating healthcare professionals at all levels, safer and effective use of insulin therapy, ensuring all appropriate patients are seen promptly by the inpatient diabetes team and avoidance of hypoglycaemia, especially overnight; however, there are still multiple barriers that need to be overcome if these objectives are to be met. Amongst the challenges identified is to overcome the well-documented clinical inertia in managing hyperglycaemia [26] , and the availability of inpatient diabetes service support, as 28% of hospital sites involved in the audit did not have inpatient diabetes nurses [2] . The majority of non-critically ill inpatients are admitted to hospital for other conditions and are under the care of nonspecialist teams [13] . General ward nurses currently have to manage an increasing number of inpatients with limited staff numbers (and even fewer at night-time). Although basalbolus insulin therapy results in lower mean daily blood glucose levels, the risk of mild hypoglycaemia is increased [27] and significant ward staff input is still required. Constant vigilance of blood glucose measurements, insulin dose administration and timing with meals contribute to the already significant workload of ward staffs, many of whom are already overburdened with other clinical duties.
There is a realization that unless effective inpatient hyperglycaemia management strategies using appropriate clinical tools are available, achieving recommended objectives will continue to be challenging in the non-critical care setting. Effective and safe adoption of technology in inpatient diabetes care may potentially be beneficial, and overcome the barriers of managing hyperglycaemia in the general ward.
Technology and innovation in inpatient diabetes management
Diabetes technology in clinical practice can be broadly divided into glucose monitoring and drug or insulin delivery. Data from the majority of modern outpatient capillary glucose monitoring devices are downloadable, allowing user interface through diabetes management software which can help facilitate clinical consultation [28] . Outpatient use of subcutaneous glucose monitoring systems is increasing, and has shown benefits in both glycaemic and patient-related outcomes [29] . A commercially available automated insulin delivery system for Type 1 diabetes, which couples real-time glucose levels with insulin delivery through a control algorithm, received US Food and Drug Administration (FDA) approval recently for outpatient use in Type 1 diabetes [30] . The role of devices and technology in inpatient glucose management is starting to increase [31, 32] , although progress has been slower compared with its outpatient counterpart. Table 1 and the sections below provide an outline of current and novel inpatient approaches together with their benefits, limitations and future outlook.
Point-of-care blood glucose monitoring
Bedside or near-patient blood glucose testing can be performed using POC-GM, which has the advantage of rapid analysis turn-around time compared with laboratory testing [33, 34] . This helps facilitate clinical decision-making and treatment in the general ward settings. POC-GM also requires a lower sample volume of blood (<1 l) for glucose measurement, compared with laboratory measurements [35] . Modern POC-GM devices allow automated linking of glucose results to hospital laboratory information system and integration with patient electronic records. This reduces the workload and time spent by ward staff manually entering glucose results, and mitigates against risk of transcription errors [36] . Use of integrated POC-GM devices in general wards has enabled real-time performance of inpatient glucose control to be monitored, whilst supporting clinical risk management and governance to help improve inpatient quality of care [37] .
Current POC-GM devices use indirect enzymatic techniques, such as glucose oxidase and glucose-1-dehydrogenase [37, 38] . In the former, glucose is oxidized to gluconic acid and hydrogen peroxide by the enzyme glucose oxidase. The concentration of blood glucose thus determines the amount of hydrogen peroxide produced, which is then measured using photometric or amperometric techniques [39] . In comparison, glucose dehydrogenase POC-GM converts glucose to gluconolactone using one of three cofactors: nicotine dinucleotide; pyrroloquinolinequinone; or flavin adenine dinucleotide. The resulting concentration of the reduced cofactor, measured using photometric or amperometric techniques, is proportional to the blood glucose concentration.
The ISO 15197-2013 is the latest international standard outlining requirement and performance validation for in vitro glucose measurement devices measuring capillary blood glucose concentrations [40] . It requires that 95% of measured glucose values fall within 0.83 mmol/l of the average measured values of the reference measurement at glucose concentrations <5.6 mmol/l, or within 15% at glucose concentrations >5.6 mmol/l; however, the ISO 15197-2013 does not distinguish the accuracy standards of POC-GM devices used by people with diabetes at home, or by healthcare professionals in the hospital settings. Physiological states, analytes imbalance and medications used in hospitalized patients may affect accuracy in hospitals [41, 42] . Based on specific issues which arise in the intended-use population, the FDA has published proposals for validation tests and stricter accuracy standards for POC-GM devices in hospital settings [43] . Used appropriately within the remit of the device performance, advances in POC testing devices may help facilitate improvements in quality and clinical outcomes. Understanding the technical aspects of these technology and devices is therefore important to ensure that potential errors and interference which may lead to adverse clinical outcomes are accounted for, or avoided. Sources of errors affecting POC-GM performance can be generally divided into pre-analytical (related to test strips, effect of alcohol swabbing and operator performance), analytical (assay or patient-related) and postanalytical (related to reporting and responding to results) factors [44] . Glucose oxidase methodology is susceptible to changes in tissue oxygenation status [45] . Hypoxic and hyperoxic states can lead to over-and underestimation of glucose measurements respectively, causing non-negligible inaccuracies leading to clinical mismanagement. Although oxygenation status does not affect glucose dehydrogenase methodology [46] , its performance is limited by the presence of non-glucose sugars, such as maltose or galactose [37] . These substances are misinterpreted as glucose by this methodological approach, thus yielding falsely high blood glucose readings. Several fatal hypoglycaemic events have been attributable to glucose dehydrogenase POC-GM because of interference from non-glucose sugars [47] . Both glucose oxidase and dehydrogenase methodologies can be affected by medications used in the general ward [48, 49] . For example, therapeutic concentrations of acetaminophen can result in lower or higher glucose measurements, and high doses of ascorbic acid can lead to falsely low glucose measurements in both methodologies. Other confounding factors affecting POC-GM measurements are summarized in Table 2 .
Electronic medical records and computerized order sets
The use of electronic health records and computerized order sets in the general ward has been adopted in several countries to support inpatient workflow and management. Computerized order sets are usually integrated into electronic patient records and can provide healthcare professionals with instructions on glucose management [50] ; however, these are bound by pre-existing inpatient hyperglycaemia guidelines or protocols, and are not designed to recommend complex insulin dose or therapy suggestions.
Remote access to electronic medical records and glucose management through computerized order systems aim to support clinical staff to provide a more efficient inpatient hyperglycaemia service. A cross-sectional study by Rushakoff et al. [51] evaluated a virtual glucose management service (vGMS) in non-obstetric adults in both non-critical and critical care over three 12-month periods (pre-vGMS, transition and vGMS). During the vGMS period, a member of the inpatient diabetes team remotely reviewed electronic glucose and insulin charts across three US academic hospitals daily, and recommended medication changes in the electronic treatment chart. Implementation of vGMS was associated with a 39% reduction in patient-days spent with hyperglycaemia (>10 mmol/l) and a 36% reduction in proportion of hypoglycaemia (<3.9 mmol/l) measurements. The number of severe hypoglycaemic events in hospital (<2.2 mmol/l) was also reduced during the vGMS compared with the pre-vGMS period (15 vs 40 events).
Clinical decision support and glucose management system
Electronic linking with modern POC-GM devices has led to the development of computerized decision support and glucose management systems, integrating glucometric information with electronic insulin prescribing [52] . This creates the opportunity to innovate inpatient glucose management using computerized insulin-treatment protocols and algorithms that are interactive, involving complex rules to support workflow and providing insulin dose advise for healthcare professionals. Intensive hands-on or online training is usually required by users of computerized or web-based support systems. In addition to ordering blood glucose monitoring and insulin prescribing, users can also flag at-risk inpatients or clinical areas for immediate review by the inpatient diabetes team [32] .
Studies evaluating efficacy and safety of these systems in noncritical care settings have showed modest improvements in glycaemia levels [53] , with overall increased adherence to glucose monitoring and appropriate insulin therapy management. The use of a computerized insulin order template in a randomized controlled study of general medical inpatients resulted in a significant reduction in mean capillary blood 
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glucose levels [12.4 (3. 2) vs 10.8 (3.7) mmol/l; P=0.004), when compared to usual care [54] . Computerized order sets also led to reduced use of subcutaneous sliding-scale insulin (25 vs 58%; P = 0.01), which is discouraged by professional societies because of safety concerns related to hypoglycaemia [52] . The transition from traditional paper-based insulin-dosing algorithms to computerized decision support systems which are integrated with clinical staff workflow, is another example of using technology to improve and standardize inpatient glycaemic management. In a randomized controlled study, a paper-based insulin-dosing algorithm for basal-bolus therapy was evaluated in 74 hospitalized non-critical care patients with Type 2 diabetes [55] . Compared with standard glycaemic management, time in target range (3Á9-10 mmol/l) and mean blood glucose levels were significantly improved in the algorithm group, albeit at a cost of higher number of hypoglycaemic events during the daytime based on sensor glucose levels (<3.9 mmol/l). The authors reported high adherence (>90%) to the algorithm-suggested insulin dose by physicians and nurses during the study. A tablet-based decision support system and insulin-dosing algorithm for basal-bolus insulin in non-critical care was tested in a non-randomized study by the same group [56] . Over 90 percent of healthcare professionals who completed usability questionnaires at the end of the study felt confident using the system to manage inpatient hyperglycaemia. Insulin-dosing errors and workflow deviations were also shown to be mitigated by the system, compared with paper-based workflow protocol use [57] . The computerized decision support and glucose management system approaches outlined above are still dependent on the ordering and implementation of glucose monitoring and insulin administration, which require significant input and support from ward staff. They also involve coordination amongst different hospital services and healthcare providers, such as clinicians, nurses and dieticians, as well as educators, pharmacy and hospital information technology services [31] . Complex computerized order sets are known to impede usability amongst prescribers, who face daily time constraints at their workplace [58] . In such situations, healthcare providers have been reported to bypass structured order sets, reverting back to the practice of using traditional subcutaneous sliding-scale insulin, thus leading to suboptimal glucose control. The use of a workflow-integrated clinical decision support system may help to facilitate complex decisionmaking processes related to inpatient glucose management. Ease of access and user interface are important factors for system designers to take into account when developing these systems. Further automation of glycaemic control systems will enable technology to play a more efficient role in reducing the burden of inpatient glucose management.
Continuous glucose monitoring
Continuous glucose monitoring (CGM) devices measure interstitial fluid glucose concentration every 1 to 5 min via subcutaneously implanted amperometric enzyme electrodes, which detect changes in current flow caused by enzymatic catalysation of glucose into hydrogen peroxide [59] . Users are able to view current glucose levels continuously, and have information related to predicted glucose levels and trends. CGM also features hypo-and hyperglycaemia alerts, which can be customized by the user as appropriate. A number of CGM devices have been approved for outpatient use to complement ambulatory capillary glucose measurement devices, and for hypo-/hyperglycaemia detection and prevention.
There are CGM devices available for use in the hospital setting, although most are only approved for use in European countries [60] . The majority of these devices use intravenous glucose measurements, which present challenges in noncritical care settings because of difficulties in obtaining/ maintaining intravascular access. There is also concern about increased risk of thrombus formation and catheter-related infections in general wards. The Sentrino CGM device, which is attached to a bedside monitor and displays glucose values every minute, was the only subcutaneous CGM system approved for hospital use (in Europe only), but has been discontinued [61] .
Approximately 5 min of a healthcare provider's time is needed to measure and obtain glucose results using a conventional POC-GM device [62] . Current guidelines recommend regular glucose monitoring, which can present a challenge because of manpower issues and time constraints. Automation of glucose monitoring by CGM may help alleviate this burden, and the resulting efficiency and time saved could be allocated to other clinical duties. There is a growing interest in the use of this technology in hospital settings as a result of the additional information provided by CGM [63] . The current, predicted (trajectory) and rate of change of glucose concentrations could help facilitate decision-making for therapy adjustments [64, 65] . In contrast, POC-GM measurements only provide intermittent 'snapshots' of glucose profiles, which can potentially miss significant glycaemic excursions in those with rapidly varying glycaemia ( Table 3 ). In comparison with intensive care unit settings, where one-to-one nursing care is available and frequent POC-GM measurements are feasible, fewer bedside glucose measurements are performed in non-critical care settings as a result of lower staffing levels [31] .
Several clinical studies comparing POC-GM and CGM in hospitalized patients have highlighted the benefits of the latter in general ward settings [66] . Schaupp et al. [67] applied blinded CGM to 84 hospitalized patients with Type 2 diabetes in a general ward, and retrospectively compared CGM values with four-daily POC-GM measurements over a period of 501 patient-days. The authors reported that the number of nocturnal hypoglycaemic episodes (<3.9 mmol/l) detected by CGM was 15-fold higher than the number detected by POC-GM. The number of hyperglycaemic episodes (>13.9 mmol/l) detected by CGM was also higher ª 2017 Diabetes UK (12.5-fold). In a recent observational study, 38 inpatients with Type 2 diabetes receiving basal-bolus insulin therapy in the general ward wore CGM devices for up to 6 days [68] . CGM values were compared with POC-GM, which was simultaneously performed at pre-and 2-h postprandial, prebedtime and 03:00 h during the study. In spite of more frequent capillary glucose measurements, more hypoglycaemic episodes were still detected by CGM (55 vs 12; P<0.01). Additionally, more than half of these episodes occurred between dinner and 06:00 h, a period when fewer capillary glucose measurements are made. Although both studies, like others, showed no difference in mean daily glucose concentrations, significantly greater numbers of hypo-and hyperglycaemic events were detected by CGM. Importantly, it highlighted CGM as a potentially valuable clinical tool in detecting occult nocturnal hypoglycaemic events, especially in inpatients known to be at increased risk of overnight hypoglycaemia [69] .
A consensus statement on the inpatient use of CGM technology in critical and non-critical care was recently published [63] . The consensus panel acknowledged the potential benefits of CGM in hospitalized patients, especially those related to hypoglycaemia reduction; however, limitations of current CGM technology were highlighted, and factors which could affect CGM performance and safety in hospital were outlined. The accuracy of most CGM devices can be affected by interference from substances (acetaminophen, ascorbic acid, dopamine, mannitol, heparin and uric acid) and impaired tissue perfusion; however, CGM studies in hospitalized patients [70, 71] and ambulatory freeliving people with diabetes [72, 73] have shown acceptable accuracy with no safety signals, and support its role in predicting and avoiding future glycaemic excursions. The ease of use by non-specialist teams and nursing staff is pertinent if CGM is to be widely adopted in the general ward setting. Because of the lag between vascular and interstitial fluid glucose, CGM sensors need to be calibrated appropriately during periods of glycaemic stability. Correct interpretation of CGM data is important to avoid the risk of 'insulin stacking', when insulin is administered based on CGM trend data by healthcare professionals with limited training in diabetes or CGM use. This may be mitigated through CGMspecific computer algorithms, which can guide insulin-dosing decisions by general ward staffs [74] . The cost of CGM is another important consideration, and evidence from welldesigned cost-effectiveness studies are needed to support CGM implementation (i.e. in reducing nursing workload, inpatient hypoglycaemia and morbidity).
Automated insulin delivery system
There continues to be an unmet need for an effective and safe therapeutic approach for inpatient glucose control. An automated system delivering insulin in a glucose-responsive fashion could potentially address this need, whilst reducing staff workload. Closed-loop insulin delivery, also known as an artificial pancreas, consists of a CGM device and an insulin pump delivery device linked together by a control algorithm that calculates the amount of insulin to be delivered based on real-time CGM measurements [75] . Autonomous glucose control can thus be potentially achieved and maintained by a closed-loop system. Manual meal-time announcement and prandial insulin boluses are currently still recommended to overcome the delay in the insulin action profile of currently available insulin analogues [76] . This 'hybrid' closed-loop approach is in contrast to a 'fully' closed-loop approach, in which user input to the control algorithm-related to meals is not required. A number of free-living ambulatory studies in Type 1 diabetes have shown that hybrid closed-loop system application significantly improves long-term glycaemic control and reduces glycaemic excursions, compared with conventional and sensor-augmented pump therapy [9, 10] . Closed-loop systems also have a favourable impact on quality of life [77] . The recent FDA approval of a hybrid closed-loop system currently makes it a realistic therapeutic option for people with Type 1 diabetes [30] .
There are few published data on the use of closed-loop systems in hospitalized patients with hyperglycaemia. The feasibility of a closed-loop system using intravascular access for glucose-sensing and insulin delivery has been reported in the critical care setting; hypoglycaemia risk and time spent managing glucose control by staff was significantly reduced during closed-loop compared with intravenous insulin infusion in one study [78] , and the proportions of patients achieving tight (5.0-6.0 mmol/l) and moderate (<8.0 mmol/l) glycaemic control were higher in the closed-loop group in another study [79] ; however, the need for and maintenance of intravascular access for these systems can present a challenge in general wards. For a viable closed-loop option in non-critical care settings, a fully closed-loop approach requiring only subcutaneous access would be preferable and practical. This would provide a pragmatic solution, with minimal input required by healthcare professionals, thus reducing workload.
The efficacy and safety of an automated subcutaneous fully closed-loop insulin delivery system in insulin-treated patients with Type 2 diabetes in the general ward was recently reported in a randomized controlled parallel-design study [11] . Participants were suboptimally controlled (mean HbA 1c >69 mmol/mol) with insulin requirements generalizable in this population (mean total daily insulin 0.6 U/kg). A fully closed-loop approach was applied, during which insulin was autonomously delivered by the control algorithm without the need for meal-time boluses or announcement by the ward staff (Fig. 1) . Compared with conventional insulin therapy, closed-loop significantly increased the proportion of time spent in the target range (5.6-10 mmol/l) by 22% and reduced time spent above target by 19%, without increasing time spent in hypoglycaemia or total amount of insulin delivered. The control algorithm autonomously adapted to each individual's insulin requirements. Thus, amongst the advantages of an automated control algorithm-directed insulin delivery system is the modulation of insulin delivery according to sensor glucose concentrations, and adaptation to changes in insulin sensitivity during periods of illness. This may benefit inpatient cohorts for whom appropriate insulin dose requirements are difficult to ascertain and current glycaemic management in hospital remains challenging (Table 3) . It is important, however, to have a planned transitionary period, as closed-loop system introduction into clinical practice may initially lead to an increase in staff workload and cost, related to device training and user support. Further longer studies are needed to evaluate the clinical outcomes and health economics of automated closedloop systems in the general ward.
Novel pharmacological approaches
The potential use of non-insulin therapy is an area of growing research and clinical interest. Therapies such as glucagon-like peptide 1 (GLP-1), dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter-2 (SGLT2) inhibitor treatment are, in principle, attractive options, because of their glucose-dependent action, low risk of hypoglycaemia and reduced staff burden [22] . Two randomized controlled studies reported that DPP-4 inhibitors, with or without basal insulin, achieved similar glycaemic control to basal-bolus insulin regimens in inpatients with Type 2 diabetes [80, 81] . Both studies recruited only patients with mild to moderate hyperglycaemia (i.e. those with HbA 1c <59 mmol/mol and total daily insulin <0.4 U/kg), thus limiting their generalizability. Additionally, this class of agents is currently contraindicated for use in those who develop heart failure [82] . Randomized studies of GLP-1 use in hospital settings are currently awaited, although these agents are associated with increased gastrointestinal adverse effects which may limit their use in unwell hospitalized patients [83] . Outpatient use of SGLT2 inhibitors have shown promising cardiovascular outcomes, but this has been associated with an increased risk of ketonaemia/ diabetic ketoacidosis and urinary tract infections. SGLT2 inhibitor use is also not currently recommended during severe illness and prolonged fasting for surgical procedures [84] . These factors may thus restrict the use of non-insulin FIGURE 1 Automated subcutaneous fully closed-loop insulin delivery prototype used in the general ward. Adapted from Thabit et al. [11] . CGM, continuous glucose monitoring.
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Inpatient diabetes technology in the National Health Service: are we there yet?
Several improvements in the care process of inpatient diabetes management have been implemented since the publication of UK national audits in recent years [2, 87] ; however, a number of unmet needs remain as several key measures are below recommended standards. Stakeholders, including professional bodies and patient organizations, such as Diabetes UK, have made recommendations to improve the quality of inpatient diabetes care in the UK [18, 88] . Timely and appropriate administration of medications and food has been highlighted to help reduce the incidence of inpatient hypoglycaemia [89] , which is associated with serious adverse events and death [25] . Amongst the recommended role of the inpatient diabetes team, comprising a dedicated inpatient diabetes nurse specialist, consultant, podiatrist and specialist dietician, is to create awareness and provide education amongst general ward staff, and help facilitate the 'safe diabetes discharge' policy. The latter includes reviewing anti-hyperglycaemic therapy prior to discharge and avoiding transcription errors through miscommunication of instructions, to mitigate against the higher re-admission rates of people with diabetes [90] . The increasing workload burden, however, means there is an urgent need for innovative approaches, to improve the effectiveness and efficiency of healthcare delivery in inpatient hyperglycaemia management.
The adoption of technology in large healthcare organisations such as the National Health Service (NHS), commonly involves a process of initiation (setting the agenda), adoption decision and implementation [91] , which includes the procurement and use of the technology. In the NHS, these processes are influenced by factors such as complexity, scale and costs [92] . In spite of emerging evidence that growth in new technology expenditure could translate to increased productivity in the NHS [93] , spending of healthcare technology per capita in the UK is lower than in Germany, Scandinavia, Switzerland and North America [94] . Reimbursement for most healthcare technology and procedures in the UK is currently in the form of national tariffs determined by the Payment by Results systems [92] . Thus, although adoption of technology, such as computerized decision support systems integrated with patient electronic records, could enable efficiency and cost savings over the medium to long term, in the context of the Payment by Results system it is perceived to be financially risky because of the short-term additional costs required to purchase, install and train staff on its use. As decrease in activity leads to reduced funding, this in turn may discourage and impede potentially novel and innovative solutions from being adopted in the NHS.
The infrastructure and application of diabetes technology currently vary in individual NHS Trusts across the UK. For example, technologies such as fully computerized patient records, electronic prescribing and wireless glucose monitoring [53, 95, 96] are available in some Trusts, but not others. Most hospitals in the UK do not have electronic platforms or workstations that allow data transfer and share between different departments, hospitals, or with primary care. In the context of inpatient hyperglycaemia, this may lead to prescription errors related to insulin and other anti-hyperglycaemic therapies when patients are transferred between wards, or discharged from hospital. For patients transferred from critical care to the general wards, POC-GM measurements and insulin dose requirements derived from electronic prescribing records can help facilitate the safe transition from intravenous to subcutaneous insulin, as per Joint British Diabetes Societies guidelines [14] .
It is acknowledged that further coordination on the uptake and diffusion of technological innovations across the NHS is needed [92] . Greater flexibility and support for individual hospitals and commissioning organizations to negotiate local tariffs will provide healthcare professionals the confidence and certainty in adopting the use of technology, and integrating it into their daily workflow. As more evidence on the use of diabetes technology such as CGM and automated insulin delivery systems in non-critical settings becomes available, greater interaction between inpatient diabetes teams, other specialties and NHS managers will be needed to identify barriers and enable factors to adopt these technologies for the benefit of people with diabetes.
Conclusions
In the face of increasing staff work burden and prevalence of inpatient diabetes, inpatient hyperglycaemia management remains challenging. Novel technologies have the potential to provide benefits to diabetes care in hospital, by improving efficacy, efficiency and safety. There is under-utilization of technology in inpatient hyperglycaemia management in the non-critical care setting, however, and as such there remains an unmet need. Ongoing studies will provide further evidence of the role of technology and the methods required to integrate it into clinical practice without disruption to usual workflow. The adoption of and investment in technologies in the NHS will require further mediation of current inpatient healthcare strategy, if the diffusion of these technologies based on best evidence and practice is to be implemented. 
